IDEXX Laboratories, Inc.

NasdaqGS:IDXX Stock Report

Market Cap: US$45.8b

IDEXX Laboratories Valuation

Is IDXX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDXX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDXX ($551.21) is trading above our estimate of fair value ($365.34)

Significantly Below Fair Value: IDXX is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDXX?

Other financial metrics that can be useful for relative valuation.

IDXX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.6x
Enterprise Value/EBITDA38.2x
PEG Ratio5.8x

Price to Earnings Ratio vs Peers

How does IDXX's PE Ratio compare to its peers?

The above table shows the PE ratio for IDXX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51.1x
EW Edwards Lifesciences
37.3x9.5%US$52.3b
GEHC GE HealthCare Technologies
28.3x14.8%US$39.3b
DXCM DexCom
83.9x20.3%US$45.4b
BDX Becton Dickinson
55x18.9%US$69.5b
IDXX IDEXX Laboratories
54.2x9.3%US$45.8b

Price-To-Earnings vs Peers: IDXX is expensive based on its Price-To-Earnings Ratio (54.2x) compared to the peer average (51.1x).


Price to Earnings Ratio vs Industry

How does IDXX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: IDXX is expensive based on its Price-To-Earnings Ratio (54.2x) compared to the US Medical Equipment industry average (35.5x).


Price to Earnings Ratio vs Fair Ratio

What is IDXX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDXX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio54.2x
Fair PE Ratio34.4x

PM vs Fair Ratio: IDXX is expensive based on its Price-To-Earnings Ratio (54.2x) compared to the estimated Fair Price-To-Earnings Ratio (34.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDXX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$554.77
US$583.92
+5.3%
13.3%US$675.00US$400.00n/a12
Feb ’25US$527.28
US$551.04
+4.5%
14.1%US$650.00US$351.00n/a12
Jan ’25US$555.05
US$521.46
-6.1%
13.6%US$600.00US$351.00n/a12
Dec ’24US$482.60
US$510.68
+5.8%
14.7%US$600.00US$351.00n/a11
Nov ’24US$395.35
US$535.74
+35.5%
14.5%US$600.00US$351.00n/a11
Oct ’24US$437.27
US$561.19
+28.3%
12.9%US$600.00US$351.00n/a11
Sep ’24US$511.29
US$565.74
+10.6%
12.8%US$625.00US$351.00n/a11
Aug ’24US$532.30
US$554.36
+4.1%
12.7%US$600.00US$351.00n/a11
Jul ’24US$502.23
US$540.80
+7.7%
13.1%US$600.00US$351.00n/a10
Jun ’24US$469.84
US$540.80
+15.1%
13.1%US$600.00US$351.00n/a10
May ’24US$489.60
US$536.20
+9.5%
14.5%US$600.00US$326.00n/a10
Apr ’24US$500.08
US$535.70
+7.1%
14.5%US$600.00US$326.00n/a10
Mar ’24US$469.10
US$532.89
+13.6%
14.9%US$600.00US$326.00n/a9
Feb ’24US$483.20
US$487.89
+1.0%
14.8%US$582.00US$326.00US$527.289
Jan ’24US$407.96
US$463.44
+13.6%
15.3%US$582.00US$326.00US$555.059
Dec ’23US$439.17
US$463.44
+5.5%
15.3%US$582.00US$326.00US$482.609
Nov ’23US$394.93
US$462.56
+17.1%
17.2%US$582.00US$326.00US$395.359
Oct ’23US$325.80
US$477.00
+46.4%
16.0%US$582.00US$326.00US$437.279
Sep ’23US$349.93
US$477.00
+36.3%
16.0%US$582.00US$326.00US$511.299
Aug ’23US$398.13
US$499.33
+25.4%
22.7%US$700.00US$326.00US$532.309
Jul ’23US$358.44
US$531.75
+48.4%
20.0%US$700.00US$326.00US$502.238
Jun ’23US$369.63
US$541.13
+46.4%
19.6%US$700.00US$326.00US$469.848
May ’23US$430.48
US$637.88
+48.2%
20.1%US$750.00US$326.00US$489.608
Apr ’23US$553.44
US$637.88
+15.3%
20.1%US$750.00US$326.00US$500.088
Mar ’23US$535.14
US$636.14
+18.9%
21.6%US$750.00US$326.00US$469.107
Feb ’23US$513.51
US$634.00
+23.5%
22.9%US$750.00US$301.00US$483.207

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.